Brisbane

Takeda to buy out Maverick in $525M bet on bringing T cells to solid tumors

Takeda Pharmaceutical and Maverick Therapeutics have been R&D partners since 2017. In buying out its partner, Takeda acquires technology and drug candidates that could offer advantages compared to CAR-T therapies, including the potential to treat solid tumors.